Audentes Therapeutics (BOLD) Tops Q2 EPS by 32c
Tweet
Share
E-mail
Get Alerts BOLD Hot Sheet
Join SI Premium – FREE
Audentes Therapeutics (NASDAQ: BOLD) reported Q2 EPS of ($0.70), $0.32 better than the analyst estimate of ($1.02).
For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- T-Mobile (TMUS) Tops Q2 EPS by 27c; offers outlook
- Quest Diagnostics (DGX) Tops Q2 EPS by 30c; updates guidance
- Mobileye (MBLY) Tops Q2 EPS by 13c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
